In Brief: BMS' ConvaTec
This article was originally published in The Gray Sheet
Executive Summary
BMS' ConvaTec: Bristol-Myers Squibb division's infection control and contamination control businesses are for sale, BMS announces Aug. 14. The businesses, which make cleaners and sterilants used by health providers and FDA-regulated manufacturers, "have performed well but do not meet the strategic objectives" of the company, BMS says. The firm acquired the units through its January 1995 purchase of Calgon Vestal Laboratories from Merck ("The Gray Sheet" Nov. 7, 1994, I&W-1). Wound management and "certain other products" acquired in that deal will remain with ConvaTec...